Partial- and full-mouth scaling and root planing in type 2 diabetic subjects: A 12-mo follow-up of clinical parameters and levels of cytokines and osteoclastogenesis-related factors

Journal of Periodontal Research

Volumn 47, Issue 1, 2012, Pages 45-54

  Santos, V R ^a   Ribeiro, F V ^a,b   Lima, J A ^a   Miranda, T S ^a   Feres, M ^a   Bastos, M F ^a   Duarte, P M ^a  

^a Guarulhos University   (Brazil)

^b PAULISTA UNIVERSITY   (Brazil)

Author keywords

Chronic periodontitis; Cytokines; Diabetes mellitus; Root planing

Indexed keywords

BIOLOGICAL MARKER; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 17; INTERLEUKIN 23; INTERLEUKIN 4; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; CHEMISTRY; CHRONIC PERIODONTITIS; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; GINGIVITIS; HUMAN; IMMUNOLOGY; MALE; METHODOLOGY; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; OSTEOCLAST; PERIODONTAL DISEASE; PERIODONTAL POCKET; PHYSIOLOGY; PREVENTIVE DENTISTRY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; TREATMENT OUTCOME;

ADULT; AGED; BIOLOGICAL MARKERS; CHRONIC PERIODONTITIS; CYTOKINES; DENTAL SCALING; DIABETES MELLITUS, TYPE 2; FEMALE; FOLLOW-UP STUDIES; GINGIVAL CREVICULAR FLUID; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-17; INTERLEUKIN-23; INTERLEUKIN-4; MALE; MIDDLE AGED; OSTEOCLASTS; OSTEOPROTEGERIN; PERIODONTAL ATTACHMENT LOSS; PERIODONTAL POCKET; PROSPECTIVE STUDIES; RANK LIGAND; ROOT PLANING; SINGLE-BLIND METHOD; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84855358174     PISSN: 00223484     EISSN: 16000765     Source Type: Journal    
DOI: 10.1111/j.1600-0765.2011.01403.x     Document Type: Article

References (52)

1. Navarro-Sanchez AB, Faria-Almeida R, Bascones-Martinez A. Effect of non-surgical periodontal therapy on clinical and immunological response and glycaemic control in type 2 diabetic patients with moderate periodontitis. J Clin Periodontol 2007;34:835-843.
2. O'Connell PA, Taba M, Nomizo A et al. Effects of periodontal therapy on glycemic control and inflammatory markers. J Periodontol 2008;79:774-783.
3. Santos VR, Lima JA, De Mendonça AC, Maximo MB, Faveri M, Duarte PM. Effectiveness of full-mouth and partial-mouth scaling and root planing in treating chronic periodontitis in subjects with type 2 diabetes. J Periodontol 2009;80:1237-1245.
4. Quirynen M, Papaioannou W, van Steenberghe D. Intraoral transmission and the colonization of oral hard surfaces. J Clin Periodontol 1996;67:986-993.
5. Greenstein G, Lamster I. Bacterial transmission in periodontal diseases: a critical review. J Clin Periodontol 1997;68:421-431.
6. Quirynen M, De Soete M, Dierickx K, van Steenberghe D. The intra-oral translocation of periodontopathogens jeopardises the outcome of periodontal therapy. A review of the literature. J Clin Periodontol 2001;28:499-507.
7. Quirynen M, Bollen CM, Vandekerckhove BN, Dekeyser C, Papaioannou W, Eyssen H. Full- vs. partial-mouth disinfection in the treatment of periodontal infections: short-term clinical and microbiological observations. J Dent Res 1995;74:1459-1467.
8. Zijnge V, Meijer HF, Lie MA et al. The recolonization hypothesis in a full-mouth or multiple-session treatment protocol: a blinded, randomized clinical trial. J Clin Periodontol 2010;37:518-525.
9. Van Dyke TE, Serhan CN. Resolution of inflammation: a new paradigm for the pathogenesis of periodontal diseases. J Dent Res 2003;82:82-90.
10. Ikezawa-Suzuki I, Shimada Y, Tai H, Komatsu Y, Tanaka A, Yoshie H. Effects of treatment on soluble tumour necrosis factor receptor type 1 and 2 in chronic periodontitis. J Clin Periodontol 2008;35:961-968.
11. Buduneli N, Buduneli E, Kütükçüler N. Interleukin-17, RANKL, and osteoprotegerin levels in gingival crevicular fluid from smoking and non-smoking patients with chronic periodontitis during initial periodontal treatment. J Periodontol 2009;80:1274-1280.
12. Santos VR, Ribeiro FV, Lima JA, Napimoga MH, Bastos MF, Duarte PM. Cytokine levels in sites of chronic periodontitis of poorly-controlled and well-controlled type 2 diabetic subjects. J Clin Periodontol 2010;37:1049-1058.
13. Reinhardt RA, Stoner JA, Golub LM et al. Association of gingival crevicular fluid biomarkers during periodontal maintenance with subsequent progressive periodontitis. J Periodontol 2010;8:251-259.
14. Teles RP, Gursky LC, Faveri M et al. Relationships between subgingival microbiota and GCF biomarkers in generalized aggressive periodontitis. J Clin Periodontol 2010;37:313-323.
15. Lamster IB, Ahlo JK. Analysis of gingival crevicular fluid as applied to the diagnosis of oral and systemic diseases. Ann N Y Acad Sci 2007;1098:216-229.
16. Schara R, Medvescek M, Skaleric U. Periodontal disease and diabetes metabolic control: a full-mouth disinfection approach. J Int Acad Periodontol 2006;8:61-66.
17. Vernal R, Dutzan N, Chaparro A, Puente J, Valenzuela MA, Gamonal J. Levels of interleukin-17 in gingival crevicular fluid and in supernatants of cellular cultures of gingival tissue from patients with chronic periodontitis. J Clin Periodontol 2005;32:383-389.
18. Tsai CC, Ku CH, Ho YP, Ho KY, Wu YM, Hung CC. Changes in gingival crevicular fluid interleukin-4 and interferon-gamma in patients with chronic periodontitis before and after periodontal initial therapy. Kaohsiung J Med Sci 2007;23:1-7.
19. Armitage GC. Development of a classification system for periodontal diseases and conditions. Ann Periodontol 1999;4:1-6.
20. Araújo MW, Hovey KM, Benedek JR et al. Reproducibility of probing depth measurement using a constant-force electronic probe: analysis of inter- and intraexaminer variability. J Periodontol 2003; 74:1736-1740.
21. Ainamo J, Bay I. Problems and proposals for recording gingivitis and plaque. Int Dent J 1975;25:229-235.
22. Santos VR, Lima JA, Gonçalves TE et al. Receptor activator of NF-κB ligand/Osteoprotegerin ratio in sites of chronic periodontitis of poorly-controlled and well-controlled type 2 diabetic subjects. J Periodontol 2010;81:1455-1465.
23. Loggner Graff I, Asklöw B, Thorstensson H. Full-mouth versus quadrant-wise scaling - clinical outcome, efficiency and treatment discomfort. Swed Dent J 2009;33:105-113.
24. Swierkot K, Nonnenmacher CI, Mutters R, Flores-de-Jacoby L, Mengel R. One-stage full-mouth disinfection versus quadrant and full-mouth root planing. J Clin Periodontol 2009;36:240-249.
25. Tomasi C, Bertelle A, Dellasega E, Wennström JL. Full-mouth ultrasonic debridement and risk of disease recurrence: a 1-year follow-up. J Clin Periodontol 2006;33:626-631.
26. Knöfler GU, Purschwitz RE, Jentsch HF. Clinical evaluation of partial- and full-mouth scaling in the treatment of chronic periodontitis. J Periodontol 2007;78:2135-2142.
27. Janket SJ, Wightman A, Baird AE, Van Dyke TE, Jones JA. Does periodontal treatment improve glycemic control in diabetic patients? A meta-analysis of intervention studies. J Dent Res 2005;84:1154-1159.
28. Darré L, Vergnes JN, Gourdy P, Sixou M. Efficacy of periodontal treatment on glycaemic control in diabetic patients: a meta-analysis of interventional studies. Diabetes & Metab 2008;34:497-506.
29. Simpson TC, Needleman I, Wild SH, Moles DR, Mills EJ. Treatment of periodontal disease for glycaemic control in people with diabetes. Cochrane Database Syst Rev 2010;12:CD004714.
30. Teeuw WJ, Gerdes VE, Loos BG. Effect of periodontal treatment on glycemic control of diabetic patients: a systematic review and meta-analysis. Diabetes Care 2010;33:421-427.
31. Albiger B, Dahlberg S, Henriques-Normark B, Normark S. Role of the innate immune system in host defence against bacterial infections: focus on the Toll-like receptors. J Intern Med 2007;261(6):511-528.
32. Fietta P, Delsante G. The effector T helper cell triade. Riv Biol 2009;102(1):61-74.
33. Tanaka S, Nakamura K, Takahasi N, Suda T. Role of RANKL in physiological and pathological bone resorption and therapeutics targeting the RANKL-RANK signaling system. Immunol Rev 2005;208:30-49.
34. Vernal R, Chaparro A, Graumann R, Puente J, Valenzuela MA, Gamonal J. Levels of cytokine receptor activator of nuclear factor κB ligand in gingival crevicular fluid in untreated chronic periodontitis patients. J Periodontol 2004;75:1586-1591.
35. Patel DN, King CA, Bailey SR et al. Interleukin-17 stimulates C-reactive protein expression in hepatocytes and smooth muscle cells via p38 MAPK and ERK1/2-dependent NF-kappaB and C/EBPbeta activation. J Biol Chem 2007;14:27229-27238.
36. Tesmer LA, Lundy SK, Sarkar S, Fox DA. Th17 cells in human disease. Immunol Rev 2008;223:87-113.
37. Oda T, Yoshie H, Yamazaki K. Porphyromonas gingivalis antigen preferentially stimulates T cells to express IL-17 but not receptor activator of NF-kappaB ligand in vitro. Oral Microbiol Immunol 2003;18:30-36.
38. Cardoso CR, Garlet GP, Crippa GE et al. Evidence of the presence of T helper type 17 cells in chronic lesions of human periodontal disease. Oral Microbiol Immunol 2009;24:1-6.
39. Ohyama H, Kato-Kogoe N, Kuhara A et al. The involvement of IL-23 and the Th17 pathway in periodontitis. J Dent Res 2009;88:633-638.
40. Boniface K, Blom B, Liu YJ, de Waal Malefyt R. From interleukin-23 to T-helper 17 cells: human T-helper cell differentiation revisited. Immunol Rev 2008;226:132-146.
41. Tan ZY, Bealgey KW, Fang Y, Gong YM, Bao S. Interleukin-23: immunological roles and clinical implications. Int J Biochem Cell Biol 2009;41:733-735.
42. Lester SR, Bain JL, Johnson RB, Serio FG. Gingival concentrations of interleukin-23 and -17 at healthy sites and at sites of clinical attachment loss. J Periodontol 2007;78:1545-1550.
43. Mosmann TR, Coffman RL. Heterogeneity of cytokine secretion patterns and functions of helper T cells. Adv Immunol 1989;46:111-147.
44. te Velde AA, Huijbens RJ, Heije K, de Vries JE, Figdor CG. Interleukin-4 (IL-4) inhibits secretion of IL-1 beta, tumor necrosis factor alpha, and IL-6 by human monocytes. Blood 1990;76:1392-1397.
45. Shapira L, van Dyke TE, Hart TC. A localized absence of interleukin-4 triggers periodontal disease activity: a novel hypothesis. Med Hypotheses 1992;39:319-322.
46. Shin DS, Park JW, Suh JY, Lee JM. The expressions of inflammatory factors and tissue inhibitor of matrix metalloproteinase-2 in human chronic periodontitis with type 2 diabetes mellitus. J Periodontal Implant Sci 2010;40:33-38.
47. Dutzan N, Vernal R, Hernandez M et al. Levels of interferon-gamma and transcription factor T-bet in progressive periodontal lesions in patients with chronic periodontitis. J Periodontol 2009;80:290-296.
48. Pradeep AR, Roopa Y, Swati PP. Interleukin-4, a T-helper 2 cell cytokine, is associated with the remission of periodontal disease. J Periodontal Res 2008;43:712-716.
49. Boyce BF, Li P, Yao Z et al. TNF-alpha and pathologic bone resorption. The Keio J Med 2005;54:127-131.
50. Garlet GP, Martins W Jr, Fonseca BA, Ferreira BR, Silva JS. Matrix metalloproteinases, their physiological inhibitors and osteoclast factors are differentially regulated by the cytokine profile in human periodontal disease. J Clin Periodontol 2004;31:671-679.
51. Talbert J, Elter J, Jared HL, Offenbacher S, Southerland J, Wilder RS. The effect of periodontal therapy on TNF-alpha, IL-6 and metabolic control in type 2 diabetics. J Dent Hyg 2006;80:7.
52. Kardeşler L, Buduneli N, Cetinkalp S, Kinane DF. Adipokines and inflammatory mediators after initial periodontal treatment in patients with type 2 diabetes and chronic periodontitis. J Periodontol 2010;81:24-33.